Minutes: Steering Board meeting 29 January 2021

The Commission raised the issue of **fraudulent offers** for [redacted] vaccine and encouraged Member States to inform the Commission (at the EC Vaccines mailbox) if they were approached or received such offers. Some MSs [redacted] confirmed that this was the case.

1. Update on the Bazaar activities

**Moderna**

The Members of the Steering Board gave a mandate to the Commission to ask from the Company **top-up doses**.

Based on the SB mandate, the Commission would revert to Moderna, asking for **top-up doses** and would try to negotiate.

The Member States were invited to all stay in the contract, in order to be covered by the contractual clauses should they wish to buy top-up doses.

The Members requested and received clarification on the price per dose.

If the negotiations on the top-up contract would be finalised in the coming days, an exceptional SB would be conveyed early next week to inform and seek the approval of the Member States.

Member States expressed concerns as some had been informed about Moderna’s

The Commission was not informed about this

The MSs called for mutual information and a coordinated approach at EU level of the changes and agreed that whenever the company would propose changes it should be invited in the SB meeting to present them to all.

MSs also outlined the importance of having clear delivery schedule for periods longer

**Pfizer/ BioNTech**

Following the presentation held last week, the Members expressed confidence that the company would present solution regarding

As regards the new APA, the Member States and the Commission underlined the importance:

- of having a clear and sustainable schedule of delivery and
- of trying to secure adaptation to new variants,
AstraZeneca

The Commission informed:

- that the redacted version of the contract would be published on the same day;
- EMA was expected to deliver its opinion in the course of the day, followed by the Commission Decision;
- most probably EMA would announce that the vaccine demonstrated around a 60% efficacy in the clinical trials and that there were not yet enough results in older participants (over 55 years old) to provide a figure for how well the vaccine will work in this group.

The Commission informed that a meeting was organised with AZ on Monday 2 February, including with CEO [redacted] to discuss supply.

The Commission informed that it had not yet

Novavax

- a draft APA was sent to Novavax on 22 January and the company was expected to provide comments and red-line mark-up;
- the JNT would review the comments and aim to meet with them.

Meeting of the Steering Board with Pfizer/BioNTech

In a follow up SB meeting on the same day, the representatives from Pfizer/BioNTech presented to the Members of the Steering Board

- The latest plan
- February and March schedule and update

The Company presented a detailed schedule which outlined the additional volume compared to the plan from 4 January.

The company presented also a revised allocation plan that would result in additional [redacted] Million doses, compared to the allocation communicated on 4 January.

Regarding the readiness status, BioNTech/Pfizer explained that it was assisting countries in their transition to 6 doses/vial.
The Company also explained to the members of the SB the mechanisms for the 2021, stressing that the company was preparing a “Declaration Form” process, which would be:

- 

The company will send a letter to the MSs explaining how the mechanisms would work and will also send a template Declaration Form.